Intro offer
100 days of Premium for just $10.
Try all Premium features for over 3 months and analyze stocks without limits.
Try 100 days for $10

$11.00
0.00%
Nasdaq, Wed, Sep 16 2026.
ISIN
US30049G1040
Symbol
EVOK

Evoke Pharma, Inc. Stock price

$11.00
+0.00 0.00% 1M
+0.00 0.00% 6M
+0.00 0.00% YTD
+5.82 112.36% 1Y
-2.92 20.98% 3Y
-145.96 92.99% 5Y
-262.60 95.98% 10Y
-1,679.56 99.35% 20Y
Nasdaq, Closing price Wed, Sep 16 2026
+0.00 0.00%
ISIN
US30049G1040
Symbol
EVOK
Industry

Is Evoke Pharma, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,134 stocks worldwide.

Key metrics

Basic
Market capitalization
$19.0m
Enterprise Value
$12.4m
Net debt
positive
Cash
$11.6m
Shares outstanding
1.7m
Valuation (TTM | estimate)
P/E
negative
P/S
1.3 | 1.2
EV/Sales
0.9 | 0.8
EV/FCF
negative
P/B
5.6
Financial Health
Equity Ratio
40.2%
Return on Equity
-76.1%
ROCE
-152.3%
ROIC
-
Debt/Equity
1.5
Financials (TTM | estimate)
Revenue
$14.4m | $16.3m
EBITDA
-
EBIT
$-5.2m
Net Income
$-5.2m
Free Cash Flow
$-3.3m
Growth (TTM | estimate)
Revenue
67.3% | 59.0%
EBITDA
-
EBIT
12.0%
Net Income
15.0%
Free Cash Flow
37.6%
Margin
Gross
97.0%
EBITDA
-
EBIT
-36.0%
Net
-36.2%
Free Cash Flow
-23.1%
More
EPS
$-2.0
FCF per Share
$-1.9
Short interest
0.5%
Employees
3
Rev per Employee
$3.4m

Evoke Pharma, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Evoke Pharma, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Evoke Pharma, Inc. forecast:

Hold
50%
Sell
50%

Financial data from Evoke Pharma, Inc.

Sep '25
+/-
%
14 14
67% 67%
100%
- Direct Costs 0.43 0.43
43% 43%
3%
14 14
68% 68%
97%
- Selling and Administrative Expenses 19 19
35% 35%
133%
- Research and Development Expense 0.06 0.06
50% 50%
0%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -5.19 -5.19
12% 12%
-36%
Net Profit -5.23 -5.23
15% 15%
-36%

In millions USD.

Don't miss a Thing! We will send you all news about Evoke Pharma, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evoke Pharma, Inc. Stock News

Positive
Proactive Investors
3 months ago
Evoke PLC (LSE:EVOK), the gambling group that owns William Hill, 888 and Mr Green, has agreed to a £243 million all-share takeover by Bally's Intralot, the Athens-listed lottery and gaming operator, sending its shares 16% higher to 46.45p. The recommended offer values Evoke at 52p per share and includes a partial cash alternative.
Positive
WSJ
3 months ago
Evoke shareholders will be entitled to receive 0.537 new Intralot shares for each Evoke share. The deal is expected completed the deal by the first quarter of 2027.
Positive
Reuters
3 months ago
William Hill ​UK owner ‌Evoke said on ​Friday ​it had agreed ⁠to ​be acquired ​by Bally's Intralot S.A. ​in ​a recommended all-share ‌deal ⁠valuing the company at ​about £243 ​million ($326.23 ⁠million).
More Evoke Pharma, Inc. News

Company Profile

Evoke Pharma, Inc. is a pharmaceutical company, which engages in the development of drugs for the treatment of gastrointestinal disorders and diseases. It develops Gimoti, with promotility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women with diabetes mellitus. The company was founded by Matthew J. D'Onofrio, Cam L. Garner, Scott L. Glenn, and David A. Gonyer in January 2007 and is headquartered in Solana Beach, CA.

Head office United States
CEO Mr. D'Onofrio
Employees 3
Founded 2007
Website evokepharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today